Научные статьи \ Прикладные науки. Медицина. Технология \ Mедицинские науки \ Патология. Клиническая медицина \ Нервная система. Невропатология. Неврология

Современные подходы к радионуклидному лечению нейробластомы (обзор литературы)

Современные подходы к радионуклидному лечению нейробластомы (обзор литературы)

Автор: Фомин Дмитрий Кириллович, Борисова Ольга Анатольевна, Назаров Андрей Александрович, Пятницкий И.А.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры

Статья в выпуске: 2 т.14, 2014 года.

Бесплатный доступ

Представлен обзор литературных данных о современных подходах к тактике лечения пациентов с нейробластомой. Показана эффективность применения различных схем радионуклидной терапии с использованием 131І-МИБГ в режиме мототерапии или при сочетании с химиотерапией. Описаны основные побочные эффекты при проведении 131І-МИБГ терапии и возможные способы их лечения.

Нейробластома, 131і-мибг, радиойодтерапия, детская онкология, химиотерапия

Короткий адрес: https://sciup.org/14955442

IDR: 14955442

The modern approaches to the radionuclide treatment of neuroblastoma (literature review)

The authors present the literature review about the modern approaches to treatment for neuroblastoma. This article shows the efficiency of different schemes of radionuclide therapy with 131I-MIBG, in combination with chemotherapy or as a monotherapy. The possible side effects during 131IMIBG therapy and the ways of their treatment are described.

Список литературы Современные подходы к радионуклидному лечению нейробластомы (обзор литературы)

  • Attiyeh E., London W., Mosse Y. et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma.//N Engl J Med. 2005; V. 353. P. 2243-2253.
  • Armour A., Mairs R., Gaze M. et al. Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature.//Br J Cancer. 1994. V. 70. P. 445-448.
  • Armour A., Cunningham S., Gaze M. et al. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro.//Br J Cancer. 1997. V. 75. P. 470-476.
  • Brans B., Laureys G., Schelfhout V., et al. Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: lack of relation to tumour differentiation in vivo.//European Journal of Nuclear Medicine. 1998. V. 25. P. 144-149.
  • Bown N., Cotterill S., Lastowska M. et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.//N Engl J Med. 1999. V. 340. P. 1954-1961.
  • Brodeur G., Pritchard J., Berthold F. et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.//Journal of Clinical Oncology. 1993. V.11 P. 1466-1477.
  • Buck J., Bruchelt G., Girgert R. et al. Specific uptake of m-iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH.,//Cancer Res. 1985. V. 45. P. 6366-6370.
  • Castellani M., Chiti A., Seregni E. et al. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.//Q J Nucl Med. 2000. V. 44. P.77-87.
  • Carlin S., Mairs R., McCluskey A. et al. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-iodobenzylguanidine by neuroblastoma tumors.//Clin Cancer Res. 2003. V. 9. P. 3338-3344.
  • Claudiani F., Garaventa A., Bertolazzi L. et al. metaiodobenzylguanidine therapy in advanced neuroblastoma.//J Nucl Biol Med. 1991. V. 35. P. 224-227.
  • De Kraker J., Hoefnagel C., Caron H., et al. First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma.//Eur J Cancer. 1995. V. 31A. P. 600-602.
  • De Kraker J., Hoefnagel K., Verschuur A. et al. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age.//Eur J Cancer. 2008. V.44. P. 551-556.
  • Dubois S., Messina J., Maris J. et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.//Journal of Clinical Oncology. 2004. V.22. P. 2452-2460.
  • DuBois S., Kalika Y., Lukens J. et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival.//J Pediatr Hematol Oncol. 1999. V. 21. P. 181-189.
  • Ehninger G., Klingebiel T., Kumbier I. et al. Stability and pharmacokinetics of m-iodobenzylguanidine in patients.//Cancer Res. 1987. V. 47. P. 6147-6149.
  • Garaventa A., Bellagamba O., Lo Piccolo M. et al. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients.//Br J Cancer. 1999. V. 81. P. 1378-1384.
  • Garaventa A., Guerra P., Arrighini A. et al. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine.//Cancer. 1991. V. 67. P. 922-928.
  • Gaze M., Chang Y., Flux G. Feasibility of dosimetry-based high-dose 13 П-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.//Cancer Biother Radiopharm. 2005. V. 20. P. 195-199.
  • Goodman M., Gurney J., Smith M. et al. Sympathetic Nervous System Tumors. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program. 1999. P. 65-72.
  • Hoefnagel C., Voute P., De Kraker J. et al. metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma.//J Nucl Biol Med. 1991. V. 35. P. 202-206.
  • Hor G., Maul F., Kornhuber B. et al. Outcome of metaiodobenzylguanidine therapy of neuroblastoma: seven years after. J Nucl Biol Med. 1991. V. 35. P. 207-215.
  • Howard J., Maris J., Kersun L. et al. Tumor response and toxicity with multiple infusions of high dose (131)I-MIBG for refractory neuroblastoma.//Pediatr Blood Cancer. 2005. V. 44. P. 232-239.
  • Howman-Giles R., Shaw P., Uren R. et al. Neuroblastoma and other neuroendocrine tumors.//Semin Nucl Med. 2007. V. 37. P. 286-302.
  • Hutchinson R., Sisson J., Miser J. et al. Long-term results of metaiodobenzylguanidine treatment of refractory advanced neuroblastoma.//J Nucl Biol Med. 1991. V. 35. P. 237-240.
  • Hutchinson R., Sisson J., Shapiro B. et al. 131-I-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma.//Am J Clin Oncol. 1992. V. 15. P. 226-232.
  • Iavarone A., Lasorella A., Servidei T. et al. Biology of metaiodobenzylguanidine interactions with human neuroblastoma cells.//J Nucl Biol Med. 1991. V. 35. P. 186-190.
  • Iavarone A., Lasorella A., Servidei T. et al. Uptake and storage of miodobenzylguanidine are frequent neuronal functions of human neuroblastoma cell lines.//Cancer Res. 1993. V. 53. P. 304-309.
  • Kang T., Brophy P., Hickeson M. et al. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.//J Pediatr Hematol Oncol. 2003 V. 25. P. 769-773.
  • Klingebiel T., Treuner J., Ehninger G., et al. -metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects.//Cancer Chemother Pharmacol. 1989. V. 25. P. 143-148.
  • Klingebiel T., Feine U., Treuner J. et al. Treatment of neuroblastoma with metaiodobenzylguanidine: long-term results in 25 patients.//J Nucl Biol Med. 1991. V. 35. P. 216-219.
  • Lashford L., Lewis I., Fielding S. et al. Phase I/F; II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.//Journal of Clinical Oncology. 1992. V. 10. P. 1889-1896.
  • Lashford L., Moyes J., Ott R. et al. The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma.//European Journal of Nuclear Medicine. 1988. V. 13. P. 574-577.
  • Lode H., Bruchelt G., Seitz G. et al. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression.//Eur J Cancer. 1995. V. 31A. P. 586-590.
  • Matthay K., Panina C., Huberty J. et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.//J Nucl Med. 2001. V. 42. P. 1713-1721.
  • Look A., Hayes F., Shuster J. et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.//Journal of Clinical Oncology. 1991. V. 9. P. 581-591.
  • Lumbroso J., Hartmann O., Schlumberger M. Therapeutic use of metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients. "Societe Francaise d'Oncologie Pediatrique" and Nuclear Medicine Co-investigators.//J Nucl Biol Med. 1991. V. 35. P. 220-223.
  • Mairs R., Livingstone A., Gaze M. et al. Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction.//Br J Cancer. 1994. V. 70. P. 97-101.
  • Mastrangelo R., Tornesello A., Lasorella A. et al. Optimal use of the 131-Imetaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma.//J Neurooncol. 1997. V. 31. P. 153-158.
  • Mastrangelo R., Tornesello A., Riccardi R. et al. A new approach in the treatment of stage IV neuroblastoma using a combination of meta-iodobenzylguanidine (MIBG) and cisplatin.//Eur J Cancer. 1995. V. 31A. P. 606-611.
  • Mastrangelo R., Tornesello A. Children's Oncology Group.//Journal of Clinical Oncology. 2005. V. 23. P. 6459-6465.
  • Mastrangelo S., Tornesello A., Diociaiuti L. et al. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.//Br J Cancer. 2001. V. 84. P. 460-464.
  • Matthay K., DeSantes K., Hasegawa B. et al. Phase I dose escalation of 131Imetaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.//Journal of Clinical Oncology. 1998. V. 16. P. 229-236.
  • Matthay K., Quach A., Huberty J. et al. 131I-Metaiodobenzylguanidine (131I-MIBG) Double Infusion with Autologous Stem Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Phase I study.//Journal of Clinical Oncology. 2008. V. 23. P. 200-215.
  • Matthay K., Huberty J., Hattner R. et al. Efficacy and safety of metaiodobenzylguanidine therapy for patients with refractory neuroblastoma.//J Nucl Biol Med. 1991. V. 35. P. 244-247.
  • Matthay K., Perez C., Seeger R. et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.//Journal of Clinical Oncology. 1998. V. 16. P. 1256-1264.
  • Matthay K., Villablanca J., Seeger R. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999. V. 341. P. 1165-1173.
  • Matthay K., Reynolds C., Seeger R. et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children’s Oncology Group study.//Journal of Clinical Oncology. 2008. V. 54. P. 432-439.
  • McCluskey A., Boyd M., Ross S. et al. meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.//Clin Cancer Res. 2005. V. 11. P. 7929-7937.
  • Meco D., Lasorella A., Riccardi A. Influence of cisplatin and doxorubicin on 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines Eur J Cancer. 1999. V. 35. P. 1227-1234.
  • Modak S., Pandit-Taskar N., Kushner B. et al. Transient sialoadenitis: A complication of (131)I-metaiodobenzylguanidine therapy.//Pediatr Blood Cancer. 2007. V. 45. P. 567-572.
  • Montaldo P., Lanciotti M., Casalaro A. et al. Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms.//Cancer Res. 1991. V. 51. P. 4342-4346.
  • Montaldo P., Carbone R., Ponzoni M. et al. gamma-Interferon increases metaiodobenzylguanidine incorporation and retention in human neuroblastoma cells.//Cancer Res. 1992. V. 52. P. 4960-4964.
  • Montaldo P., Raffaghello L., Guarnaccia F. et al. Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells.//Int J Cancer. 1996. V. 67. P95-100.
  • Schmidt M., Lal A., Seeger R. et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.//Journal of Clinical Oncology. 2005. V. 23. P. 6474-6480.
  • Seeger R., Brodeur G., Sather H., et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.//N Engl J Med. 1985. V. 313. P. 1111-1116.
  • Sisson J., Shapiro B., Hutchinson R. et al. Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine.//European Journal of Nuclear Medicine. 1994. V. 21. P. 46-52.
  • Shimada H., Chatten J., Newton W., Jr et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas.//J Natl Cancer Inst. 1984. V. 73. P. 405-416.
  • Smets L., Loesberg C., Janssen M. et al. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells.//Cancer Res. 1989. V. 49. P. 2941-2944.
  • Treuner J., Feine U., Niethammer D. et al. Scintigraphic imaging of neuroblastoma with iodobenzylguanidine.//Lancet. 1984. V. 1. P. 333-334.
  • Troncone L., Rufini V., Riccardi R. The use of metaiodobenzylguanidine in the treatment of neuroblastoma after conventional therapy.//J Nucl Biol Med. 1991. V. 35. P. 232-236.
  • Voute P., van der Kleij A., De Kraker J. et al. Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV.//Eur J Cancer. 1995. V. 31A. P. 596-600.
  • Wafelman A., Nortier Y., Rosing H., et al. Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance.//Nucl Med Commun. 1995. V. 16. P. 767-772.
  • Shimada H., Chatten J., Newton W. et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas.//J Natl Cancer Inst. 1984. V. 73. P. 405-416.
  • Cunningham S., Boyd M., Brown M. et al. A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma.//Med Pediatr Oncol. 2000. V. 35. P. 708-711.
  • Matthay K., Panina C., Huberty J. et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.//J Nucl Med. 2001. V. 42. P. 1713-1721.
  • Matthay K., Yanik G., Messina J. et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.//Journal of Clinical Oncology. 2007. V. 25. P. 1054-1060.
  • Brans B., Monsieurs M., Laureys G. et al. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking.//Med Pediatr Oncol. 2002. V. 38. P. 41-46.
  • Dubois S., Messina J., Maris J. et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.//Journal of Clinical Oncology. 2004. V. 22. P. 2452-2460.
  • Van Santen H., de Kraker J., van Eck B. et al. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma.//Cancer. 2002. V. 94. P. 2081-2089.
  • Van Santen H., de Kraker J., Vulsma T. Endocrine late effects from multi-modality treatment of neuroblastoma.//Eur J Cancer. 2005. V. 41. P. 1767-1774.
Еще
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp